Sévan Kaloustian has taken the role of Managing Director of Janssen Johnson & Johnson’s Pharma Companies in Romania as of the end of last year. Sévan Kaloustian was previously Business Manager for Janssen Poland.
During his ten-year experience within Janssen, Sévan Kaloustian played a key part in facilitating the patients’ access to the company’s portfolio of innovating medicines. He was also director of the Commercial Strategy worldwide on neurodegenerative diseases in New Jersey, USA.
Sévan Kaloustianhas a PhD in pharmacology and a master degree in pharma economy at Montreal University, Canada. He also has a postdoctoral course at Sinica Academy in Taiwan and a curse on digital transformation of industries at Columbia Business School, New York.
Kaloustian stated that the strategy this year will be to further develop the presence of Janssen in Romania and that the company’s priority will be to improve the Romanian patients’ access to innovative drugs. He also said they will continue the dialogue with the Romanian health authorities to find a common solution on compensating the innovative medicines and to enable their access to the local patients.
Janssen has provided new treatment options in the past year to the patients diagnosed with myeloma, chronic leukemia, prostate cancer, psoriasis and multiple sclerosis. According to Kaloustian, the company’s priorities will focus on the patients with multiple sclerosis who suffer of immune syndromes or cancer.
He is taking over the Managing Director position from Christian Rodseth, who took over a global position within the company.